•Oculis's phase 3 DME eye drop trial fails primary goals•Visionix and iCare officially merge portfolios•Outlook resubmits wet AMD BLA for bevacizumab after FDA appeal win •Leadership watch: Optivate, TVC, Ocuco name new executives•National Academy of Opticianry and United Opticians Association kick-start potential merger•Oculis's phase 3 DME eye drop trial fails primary goals•Visionix and iCare officially merge portfolios•Outlook resubmits wet AMD BLA for bevacizumab after FDA appeal win •Leadership watch: Optivate, TVC, Ocuco name new executives•National Academy of Opticianry and United Opticians Association kick-start potential merger
HEADLINES
FEATURED
Investigational eye drop acts as a replacement for lacritin by restoring homeostasis to the ocular surface; phase 2 trial initiation is underway.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
